EGFR and neoplasm: By targeting the tyrosine kinase site and binding to the tyrosine kinase receptor domain covalently and irreversibly, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can block the signaling pathway that activated in various neoplasms, resulting in especially effective treatment for cancer (82).